- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (26)
4 result(s) found for: Mebendazole.
Displaying page 1 of 1.
EudraCT Number: 2016-000728-24 | Sponsor Protocol Number: MEBENDAZOLGAI3003 | Start Date*: 2016-03-01 |
Sponsor Name: Janssen Research & Development, LLC | ||
Full Title: A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment o... | ||
Medical condition: Helminth infections | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-001830-91 | Sponsor Protocol Number: MetabolicCancer001 | Start Date*: 2017-05-19 |
Sponsor Name:Health Clinics Limited | ||
Full Title: A NON RANDOMISED, NON BLINDED REAL WORLD STUDY OF THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF METABOLIC MEDICINES FOR THE TREATMENT OF CANCER COMPARED AGAINST HISTORICAL CONTROLS | ||
Medical condition: Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001226-42 | Sponsor Protocol Number: MEBENDAZOLGAI3002 | Start Date*: 2015-04-09 | |||||||||||
Sponsor Name:Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |||||||||||||
Full Title: An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive | |||||||||||||
Medical condition: Soil-transmitted helminth (STH) infections | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004163-12 | Sponsor Protocol Number: RP2017-001 | Start Date*: 2018-01-28 | |||||||||||
Sponsor Name:ReposPharma | |||||||||||||
Full Title: A phase 2a TDM-guided clinical study on the safety and efficacy of mebendazole in patients with advanced gastrointestinal cancer or cancer of unknown origin | |||||||||||||
Medical condition: Squamous cell cancer or adenocarcinoma, including primary cancer of the liver, of the gastrointestinal tract or cancer of unknown origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
